Singh S, Sharma D R, Chaudhary A
University of South Australia, Adelaide.
J Indian Med Assoc. 1999 Aug;97(8):346-7.
The dizziness associated with vertiginous disorders is often accompanied with nausea and/or vomiting. Antiemetic effect of prochlorperazine (PCZ) is diminished by its low bioavailability owing to a significant gastric and hepatic first pass effect. This effect could be further diminished by likelihood of regurgitation of nauseating patients further limiting the therapeutic effect of oral PCZ. A buccal preparation achieves higher plasma concentrations through direct systemic absorption. In this study buccal prochlorperazine (Bukatel) was compared for its efficacy and tolerability with commonly used metoclopramide. Bukatel was well tolerated and well rated by both patients and investigators with no adverse effects on buccal mucosa and causing less drowsiness and sedation. Results indicate that Bukatel is safe and effective for the treatment of nausea and/or vomiting in patients suffering from vertiginous disorders and could be safely and strongly recommended as an alternative to less bioavailable and indiscriminately used oral metoclopramide tablets.
与眩晕症相关的头晕通常伴有恶心和/或呕吐。由于显著的胃和肝首过效应，氯丙嗪（PCZ）的生物利用度较低，其止吐效果因此减弱。恶心患者反流的可能性可能会进一步降低这种效果，从而进一步限制口服PCZ的治疗效果。颊部制剂通过直接全身吸收可达到更高的血浆浓度。在本研究中，对颊部氯丙嗪（Bukatel）与常用的甲氧氯普胺的疗效和耐受性进行了比较。Bukatel耐受性良好，患者和研究人员对其评价都很高，对颊黏膜无不良反应，且嗜睡和镇静作用较小。结果表明，Bukatel对于治疗患有眩晕症的患者的恶心和/或呕吐是安全有效的，并且可以作为生物利用度较低且使用不当的口服甲氧氯普胺片的替代品被安全且强烈推荐。
